Vaccinex : ASCO Conference Presentation - MarketScreener
Correlative and spatial biomarker analysis of a phase 1/2b study to evaluate PEPINEMAB IN COMBINATION WITH PEMBROLIZUMAB for first-linetreatment...
Source: marketscreener.com
📰 Barbara Burtness News
Barbara Burtness News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Barbara Burtness. Real-time updates on events, politics, business and more.
Georgetown Lombardi Visiting Professor and Grand Rounds Lecture Series: "Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer"
Title: “Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer” Presented by: Barbara Burtness, MD Professor of Medicine, Department of Medical Oncology Yale School of Medicine Location: New Research Building Auditorium with Zoom option Lecture Series Presented by Georgetown Lombardi Comprehensive Cancer Center About the Speaker: Barbara Burtness, MD, is professor of medicine (Medical Oncology) […]
Barbara Burtness Department Of Medical Oncology Yale School Of Medicine Research Building Auditorium Lethal Therapy Negative Head
Source: georgetown.edu
VIC-1911 With/Without Sotorasib Under Investigation in KRAS G12C Inhibitor–Resistant and –Naïve NSCLC
Sarah Goldberg, MD, MPH, highlights the mechanism of action of VIC-1911, expands on its ongoing investigation in the phase 1 trial, and sheds light on next steps planned for the agent’s investigation in KRAS G12C–mutant non–small cell lung cancer.
New Haven United States Barbara Burtness Sarah Goldberg Hematology Program Oncology At Yale School Of Medicine
Source: onclive.com
Combination exhibits 'impressive' activity in HPV-negative head and neck cancer
The combination of ficlatuzumab and cetuximab extended PFS for patients with pan-refractory recurrent or metastatic head and neck squamous cell carcinoma, according to randomized phase 2 study results.The benefit appeared confined to individuals with HPV-negative disease, and a phase 3 trial to further evaluate the regimen in that population is planned.
Juliee Bauman Eli Lilly Barbara Burtness Cetuximab Erbitux George Washington University Cancer Center Yale Cancer Center
Source: healio.com
Dr Burtness on the Exploration of VIC1911 and Adavosertib in HNSCC and Lung Cancer
Barbara Burtness, MD, discusses preclinical data on the combination of VIC1911 and adavosertib in head and neck squamous cell carcinoma and lung cancer.
Barbara Burtness Yale Cancer Center Medical Oncology Developmental Therapeutics Head Amp Neck Cancers Onclive Tv
Source: onclive.com
Yale Scientists Seek to Shift Treatment of Kidney Damage
For the first time, there is a potential targeted treatment for kidney injury caused by cisplatin, a widely used anti-cancer drug.
Source: yale.edu
Yale Scientists Seek to Shift Treatment of Kidney Disease
Yale Scientists Seek to Shift Treatment of Kidney Disease
Source: yale.edu